Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0000920465-21-000005
Filing Date
2021-02-02
Accepted
2021-02-02 17:20:01
Documents
1
Period of Report
2021-01-15

Document Format Files

Seq Description Document Type Size
1 FORM 4/A wf-form4a_161230438355385.html 4/A  
1 FORM 4/A wf-form4a_161230438355385.xml 4/A 3568
  Complete submission text file 0000920465-21-000005.txt   4960
Mailing Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121 858-207-4264
LA JOLLA PHARMACEUTICAL CO (Issuer) CIK: 0000920465 (see all company filings)

EIN.: 330361285 | State of Incorp.: CA | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Business Address
Hearne Michael S (Reporting) CIK: 0001759910 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-36282 | Film No.: 21582725